Skip to main content
logo
Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
23.30
-0.64 (-2.67%)
Sep 11, 2026, 4:00 PM EDT - Market closed

Aktis Oncology Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
10.066.51.49--
Revenue Growth
576.53%336.92%---
Gross Profit
-68.22-60.95-39.47-25.92-
Operating Income
-87.18-74.68-52.05-34.79-19.76
Net Income
-73.14-63.73-43.98-28.64-17.93
Earnings Per Share
-2.77-78.34-62.46-46.55-34.65
EPS Growth
-----

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
517.32226.79297.1797.86128.6
Total Debt
11.2411.5512.0113.41.78
Net Cash (Debt)
506.08215.24285.1684.46126.82
Net Cash Growth
77.47%-24.52%237.63%-33.40%-
Net Cash Per Share
19.17264.58404.96137.29245.11

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-75.29-64.1314.76-30-18.13
Capital Expenditures
-9.27-9.58-2.86-3.76-2.31
Free Cash Flow
-84.57-73.7111.9-33.77-20.43
Free Cash Flow Growth
-----

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Margin
-866.63%-1149.52%-3500.34%--
Pretax Margin
-727.04%-980.93%-2957.63%--
Profit Margin
-727.04%-980.93%-2957.63%--
FCF Margin
-840.62%-1134.54%800.27%--